Gilead expands Arcellx cancer cell therapy deal
Bio Pharma Dive
NOVEMBER 15, 2023
The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027.
Wed.Nov 15, 2023
299 
Signal: Pfizer cuts 500 UK jobs in restructuring after posting Q3 loss
Pharmaceutical Technology
NOVEMBER 15, 2023
The company has struggled this year on the back of reduced Covid-19 medication sales and is now streamlining costs.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
A gene editing biotech’s struggles end with reverse merger
Bio Pharma Dive
NOVEMBER 15, 2023
Since halting work on a sickle cell treatment early this year, Graphite Bio has laid off staff, shed assets and, now, agreed to be subsumed via a merger with Lenz Therapeutics.
NHS sets sights on ending cervical cancer by 2040 with HPV vaccine drive
Pharmaceutical Technology
NOVEMBER 15, 2023
Chief executive Amanda Pritchard says vaccination and screening could make eliminating cervical cancer a reality in the next two decades.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Mastering Your Body’s Internal Clock Could Be The Key to Success
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 15, 2023
Timing is everything. For early risers and late-nighters alike, listening to your internal clock may be the key to success. From the classroom to the courtroom and beyond, people perform best on challenging tasks at a time of day that aligns with their circadian rhythm.
Alkermes separates cancer drug business as new company Mural
Bio Pharma Dive
NOVEMBER 15, 2023
Now independent Mural Oncology will focus on advancing a pipeline of engineered cytokines for cancer, while Alkermes has recast itself as a “pure-play” neuroscience company.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Cambridge University spinout raises £48m to advance T-cell therapies
Pharmaceutical Technology
NOVEMBER 15, 2023
T-Therapeutics plans to use the Series A funds to develop T-cell therapies for cancer and auto-immune disorders.
November 15, 2023: In This Friday’s PCT Grand Rounds, Results From the Nudge Demonstration Project
Rethinking Clinical Trials
NOVEMBER 15, 2023
In this Friday’s PCT Grand Rounds, Michael Ho and Sheana Bull of the University of Colorado will present “Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications: Results From the Nudge Study.” The Grand Rounds session will be held on Friday, November 17, 2023, at 1:00 pm eastern. Nudge is an NIH Pragmatic Trials Collaboratory Demonstration Project.
UK JCVI recommends chickenpox vaccine in early childhood
Pharmaceutical Technology
NOVEMBER 15, 2023
The UK JCVI has recommended the addition of chickenpox vaccine to the country's routine immunisation programme for children.
Study shows how congenital heart disease affects blood supply before birth
Pharma Times
NOVEMBER 15, 2023
CHD is a common birth defect that affects the development of the heart and brain - News - PharmaTimes
Atreca downsizes again to focus on antibody-drug conjugate programmes
Pharmaceutical Technology
NOVEMBER 15, 2023
Atreca has made significant cuts to its workforce (by 40%) for the second consecutive quarter in 2023 in an effort to cut costs.
Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity
Fierce Pharma
NOVEMBER 15, 2023
In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival. | In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival.
Evaluating the top five sterilisation techniques for parenteral packaging
Pharmaceutical Technology
NOVEMBER 15, 2023
The use of validated methods for sterilising primary packaging before aseptic fill-and-finish plays a critical role in patient safety.
JCVI advises UK government on gonorrhoea and mpox vaccinations
Pharma Times
NOVEMBER 15, 2023
Both programmes will be offered to those most at risk of developing STIs - News - PharmaTimes
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
A new era for pMDI propellants
Pharmaceutical Technology
NOVEMBER 15, 2023
Is the pharmaceutical industry prepared to phase out HFAs used in pressurised metered-dose inhalers (pMDI) for the treatment of asthma?
The evolving landscape of medicinal cannabis and its synergy with pharmaceutical giants
pharmaphorum
NOVEMBER 15, 2023
The evolving landscape of medicinal cannabis and its synergy with pharmaceutical giants Nicole.
COP27: Have we committed to our goals?
Pharmaceutical Technology
NOVEMBER 15, 2023
Despite negotiations being ongoing since COP27, they have been slowed down by a lot of disagreements on how the fund will work.
2seventy suffers sales slump on high production charges for BMS-partnered CAR-T med Abecma
Fierce Pharma
NOVEMBER 15, 2023
If you’re curious about the pitfalls of CAR-T drug commercialization, look no further than Bristol Myers Squibb’s Abecma partner 2seventy bio. | After reporting a sizable revenue decline for its BMS-parntered multiple myeloma cell therapy in 2023’s third quarter, 2seventy stands out as a prime example of the dangers of scaling up a process before suffering lower-than-expected demand, one group of analysts contends.
Kesin Pharma expands antibiotic reach with liquid suspension approval
Pharmaceutical Technology
NOVEMBER 15, 2023
The liquid suspension requires no preparation or refrigeration and treats bacterial infections such as rosacea and pelvic inflammatory disease.
Vertex, CRISPR Win World’s First Approval for CRISPR-Edited Therapy from UK
BioSpace
NOVEMBER 15, 2023
The U.K.’s Medicines and Healthcare products Regulatory Agency on Thursday provided conditional marketing authorization for Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited therapy exa-cel.
Autifony and Jazz enter $770.5m drug development deal
Pharmaceutical Technology
NOVEMBER 15, 2023
Autifony Therapeutics and Jazz Pharmaceuticals have signed a $770.5m deal for the discovery and development of drug candidates.
Germany considers banning the export of Novo Nordisk's Ozempic
Fierce Pharma
NOVEMBER 15, 2023
How popular have Novo Nordisk’s semaglutide drugs become for weight loss in Europe? | How popular have Novo Nordisk’s semaglutide drugs become for weight loss in Europe? The craze is such that Germany’s drug regulator is considering banning the export of Ozempic, according to a report in Der Spiegel magazine.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Almirall and Absci link for AI-driven dermatological drug development
Pharmaceutical Technology
NOVEMBER 15, 2023
Almirall has entered into a collaboration with Absci for the development and commercialisation of new treatments for dermatological ailments.
CorMedix gains hard-fought approval for combo drug that reduces risk of catheter infection during dialysis
Fierce Pharma
NOVEMBER 15, 2023
CorMedix went through a lot to secure its FDA approval for DefenCath. | CorMedix went through a lot to secure its FDA approval for DefenCath. There was a reorganization, a CEO change, an exit from Europe, two complete response letters and a switch of manufacturers and suppliers. And it took a novel pathway for the approval to finally come through on Wednesday.
BIO-Europe 2023: Pharma balances on shaky financial and legislative footing
Pharmaceutical Technology
NOVEMBER 15, 2023
At BIO-Europe 2023, experts highlighted challenges in fundraising and concerns about impending EU legislative changes.
UK feels the chill of Pfizer’s cost-cutting wind
pharmaphorum
NOVEMBER 15, 2023
UK feels the chill of Pfizer’s cost-cutting wind Phil.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Starry Soda: PepsiCo’s Lemon-Lime Soda Nears Its First Birthday
XTalks
NOVEMBER 15, 2023
Starry soda, Pepsi’s innovative entry in the lemon-lime soda market, has nearly completed its first year on the market. Introduced in January 2023, this strategic move was aimed at competing with Sprite, Coca-Cola’s dominant lemon-lime beverage, which boasts a seven percent share in the $82 billion US soda market. Sierra Mist, Pepsi’s previous contender, only managed to secure about 0.1 percent of this market share.
Elucid’s $80m round heads latest digital health financings
pharmaphorum
NOVEMBER 15, 2023
Elucid’s $80m round heads latest digital health financings Phil.
Astellas Sees Path Forward for Gene Therapy Despite Four Patient Deaths
BioSpace
NOVEMBER 15, 2023
The Japanese pharma contends that an analysis of the four deaths in its AT132 gene therapy clinical trial shows it is still viable as a potential treatment for a fatal, rare genetic disease.
Bayer pulls Aliqopa from US for follicular lymphoma
pharmaphorum
NOVEMBER 15, 2023
Bayer pulls Aliqopa from US for follicular lymphoma Phil.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content